Skip to main content

Table 4 Mean base case results

From: Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Country

Results

LYs

QALYs

Costs (USD)

ICER ($/QALY)

ICER ($/LY)

Congo

No Tzb arm

8.88

7.72

2588

20,520

19,701

Tzb arm

9.89

8.69

22,585

Diffrence

1.01

0.97

19,997

Ethiopia

No Tzb arm

8.87

7.71

3541

19,990

19,384

Tzb arm

9.90

8.70

23,457

Diffrence

1.03

1.00

19,916

Guinea

No Tzb arm

8.65

7.52

2955

20,692

20,025

Tzb arm

9.65

8.48

22,898

Diffrence

1.00

0.96

19,943

Kenya

No Tzb arm

8.96

7.79

7467

19,601

18,709

Tzb arm

10.03

8.80

27,448

Diffrence

1.07

1.02

19,982

Namibia

No Tzb arm

8.69

7.54

25,549

19,818

19,125

Tzb arm

9.72

8.53

45,173

Diffrence

1.03

0.99

19,624

Nigeria

No Tzb arm

8.51

7.39

14,066

21,697

21,321

Tzb arm

9.43

8.29

33,628

Diffrence

0.92

0.90

19,561

Rwanda

No Tzb arm

8.98

7.80

3919

19,751

19,004

Tzb arm

10.03

8.81

23,894

Diffrence

1.05

1.01

19,975

Uganda

No Tzb arm

8.79

7.63

3793

20,477

19,806

Tzb arm

9.80

8.61

23,738

Diffrence

1.01

0.97

19,945

Zambia

No Tzb arm

8.75

7.60

7116

20,330

19,473

Tzb arm

9.77

8.58

27,074

Diffrence

1.02

0.98

19,958

Zimbabwe

No Tzb arm

8.57

7.44

5458

20,537

20,086

Tzb arm

9.56

8.41

25,303

Diffrence

0.99

0.97

19,845

South Africa

No Tzb arm

8.76

7.61

31,160

19,534

18,719

Tzb arm

9.83

8.63

51,119

Diffrence

1.07

1.02

19,960

  1. The standard error for LYs, QALYs, trastuzumab cost and no trastuzumab cost ranged from 0.052 LYs to 0.056 LYs, 0.049 QALYs to 0.053 QALYs, 27 USD to 328 USD, and 27 USD to 324 USD respectively